Top-Rated StocksTop-RatedNASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free KRYS Stock Alerts $177.93 +0.73 (+0.41%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$175.99▼$180.1250-Day Range$108.01▼$179.3552-Week Range$77.10▼$189.97Volume392,908 shsAverage Volume399,658 shsMarket Capitalization$5.03 billionP/E Ratio2,224.40Dividend YieldN/APrice Target$157.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Krystal Biotech alerts: Email Address Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside11.4% Downside$157.67 Price TargetShort InterestHealthy7.92% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.54Based on 4 Articles This WeekInsider TradingSelling Shares$6.54 M Sold Last QuarterProj. Earnings Growth129.19%From $1.61 to $3.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.88 out of 5 starsMedical Sector219th out of 938 stocksBiological Products, Except Diagnostic Industry28th out of 154 stocks 1.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $157.67, Krystal Biotech has a forecasted downside of 11.4% from its current price of $177.93.Amount of Analyst CoverageKrystal Biotech has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.92% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 10.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 2.0 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Krystal Biotech this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows16 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,535,591.00 in company stock.Percentage Held by Insiders17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow by 129.19% in the coming year, from $1.61 to $3.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 2,224.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 141.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 2,224.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 218.08.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesMarch 12, 2024 | insidertrades.comKrystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells $4,274,000.00 in StockMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 26, 2024 | markets.businessinsider.comAttovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory BoardsMarch 23, 2024 | americanbankingnews.comTenaya Therapeutics (NASDAQ:TNYA) versus Krystal Biotech (NASDAQ:KRYS) Critical ComparisonMarch 16, 2024 | finance.yahoo.comKRYS Apr 2024 180.000 callMarch 16, 2024 | finance.yahoo.comKRYS Apr 2024 145.000 putMarch 16, 2024 | finance.yahoo.comKRYS Aug 2024 210.000 callMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 15, 2024 | bizjournals.comThese are the next generation of biotech superstars in the Bay AreaMarch 14, 2024 | finance.yahoo.comKRYS Mar 2024 210.000 callMarch 14, 2024 | finance.yahoo.comKRYS May 2024 210.000 callMarch 6, 2024 | msn.comKrystal Biotech confirms cancellation from Cowen conference due to CEO sicknessMarch 4, 2024 | ca.finance.yahoo.comKRYS May 2024 200.000 putMarch 2, 2024 | finance.yahoo.comChief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)March 1, 2024 | benzinga.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 TodayMarch 1, 2024 | fool.com2 Stocks That Could Turn $1,000 Into $2,500 in 5 YearsFebruary 28, 2024 | seekingalpha.comKrystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comKrystal Biotech to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comKrystal Biotech to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | seekingalpha.comKrystal Biotech's Future Brightens With Vyjuvek's Robust LaunchFebruary 27, 2024 | markets.businessinsider.comKrystal Biotech Analysts Increase Their Forecasts Following Q4 ResultsFebruary 27, 2024 | markets.businessinsider.comBuy Rating for Krystal Biotech Amidst Strong Vyjuvek Sales and Sizable Market OpportunityFebruary 27, 2024 | finance.yahoo.comQ4 2023 Krystal Biotech Inc Earnings CallFebruary 26, 2024 | marketwatch.comKrystal Biotech Shares Climb on Unexpected 4Q ProfitFebruary 26, 2024 | finance.yahoo.comKrystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial ResultsSee More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees229Year Founded2017Price Target and Rating Average Stock Price Target$157.67 High Stock Price Target$195.00 Low Stock Price Target$118.00 Potential Upside/Downside-11.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio2,237.65 Forward P/E Ratio111.17 P/E GrowthN/ANet Income$10.93 million Net MarginsN/A Pretax Margin25.44% Return on Equity-13.31% Return on Assets-12.61% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.55 Sales & Book Value Annual Sales$50.70 million Price / Sales99.87 Cash FlowN/A Price / Cash FlowN/A Book Value$27.60 per share Price / Book6.49Miscellaneous Outstanding Shares28,290,000Free Float23,483,000Market Cap$5.06 billion OptionableOptionable Beta0.86 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 59)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 59)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 42)Executive VP & Chief Accounting Officer Comp: $528.87kMr. John ThomasGeneral Counsel & Corporate SecretaryMr. John KarakkalVice President of North American Sales & MarketingMs. Christine WilsonHead of U.S. Sales and MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 55)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOImmunovantNASDAQ:IMVTCRISPR TherapeuticsNASDAQ:CRSPIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 100 shares on 3/22/2024Ownership: 0.001%Vanguard Group Inc.Bought 35,632 shares on 3/11/2024Ownership: 8.610%Suma KrishnanSold 25,000 sharesTotal: $4.27 M ($170.96/share)Goldman Sachs Group Inc.Bought 43,709 shares on 3/1/2024Ownership: 0.806%Kathryn RomanoSold 5,000 sharesTotal: $829,400.00 ($165.88/share)View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price target for 2024? 9 Wall Street analysts have issued 12 month price targets for Krystal Biotech's stock. Their KRYS share price targets range from $118.00 to $195.00. On average, they anticipate the company's stock price to reach $157.67 in the next twelve months. This suggests that the stock has a possible downside of 11.4%. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2024? Krystal Biotech's stock was trading at $124.06 at the beginning of the year. Since then, KRYS shares have increased by 43.4% and is now trading at $177.93. View the best growth stocks for 2024 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, February, 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The business earned $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same quarter last year, the firm earned ($1.25) EPS. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.63%), Vanguard Group Inc. (8.61%), Jennison Associates LLC (2.57%), Dimensional Fund Advisors LP (1.95%), Price T Rowe Associates Inc. MD (1.51%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRYS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.